OP Asset Management Ltd Purchases New Position in BioCryst Pharmaceuticals, Inc. $BCRX

OP Asset Management Ltd purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the first quarter, HoldingsChannel.com reports. The firm purchased 1,252,863 shares of the biotechnology company’s stock, valued at approximately $11,927,000.

Several other large investors have also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. raised its stake in shares of BioCryst Pharmaceuticals by 403.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 26,797 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 21,472 shares during the last quarter. Invesco Ltd. increased its holdings in BioCryst Pharmaceuticals by 40.8% during the 4th quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company’s stock valued at $10,568,000 after purchasing an additional 392,521 shares in the last quarter. Mackenzie Financial Corp raised its position in BioCryst Pharmaceuticals by 16.6% in the 4th quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company’s stock valued at $1,152,000 after purchasing an additional 21,411 shares during the last quarter. NewEdge Advisors LLC acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth $390,000. Finally, XTX Topco Ltd acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth $133,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $9.97 on Thursday. The company has a fifty day moving average price of $8.88 and a two-hundred day moving average price of $8.23. The firm has a market capitalization of $2.53 billion, a PE ratio of -5.60 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $10.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. During the same period last year, the company earned $0.20 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BCRX. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wedbush decreased their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Citizens Jmp upped their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $20.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.